Affordable Access

deepdyve-link
Publisher Website

Cellular Adhesion and the Endothelium

Authors
  • Kutlar, Abdullah
  • Embury, Stephen H.1, 2, 3, 2, 4, 5
  • 1 Sickle Cell Center
  • 2 Department of Medicine
  • 3 Georgia Regents University
  • 4 University of California San Francisco School of Medicine
  • 5 Vanguard Therapeutics, Inc
Type
Published Article
Journal
Hematology/Oncology Clinics of North America
Publisher
Elsevier
Publication Date
Jan 01, 2014
Volume
28
Issue
2
Pages
323–339
Identifiers
DOI: 10.1016/j.hoc.2013.11.007
Source
Elsevier
Keywords
License
Unknown

Abstract

P-selectin on endothelial cell surfaces is central to impaired microvascular blood flow in sickle cell disease (SCD). Restoration of blood flow is expected to provide therapeutic benefit for SCD patients, whatever the mechanism of action of the treatment. Long-term oral administration of a P-selectin–blocking agent potentially improves blood flow and averts acute painful vaso-occlusive crises in patients with SCD. This review focuses on the pathophysiology of the impairment of microvascular blood flow in SCD with an emphasis on the role of P-selectin and summarizes the status of development of antiselectin therapies as a means of improving microvascular flow.

Report this publication

Statistics

Seen <100 times